Carolyn Rohrer Vitek

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
The level of CYP2D6 metabolic activity can be predicted by pharmacogenomic testing, and concomitant use of clinical decision support has the potential to prevent adverse effects from those drugs metabolized by this enzyme. Our initial findings after implementation of clinical decision support alerts integrated in the electronic health records suggest high(More)
  • 1